State legislatures and pharmacy boards build their own rules for compounded GLP-1s

State legislatures and pharmacy boards are building their own restrictions on compounded GLP-1 medications and peptides, a layer of rules that sits on top of federal requirements, according to a regulatory analysis published August 16, 2026 ^[1]. The analysis, published by PeptideLaws.com and drawn from reporting by JD Supra, says states are acting through licensing authority, pharmacy practice acts and consumer protection statutes ^[1].

Measures described in that analysis include tighter conditions on compounding GLP-1 products, closer scrutiny of telehealth prescribing arrangements that link out-of-state patients with compounded peptides, and more disclosure or labeling duties aimed at consumers ^[1]. It does not say which states adopted which of those measures, and no state-by-state breakdown of the requirements has been reported ^[1].

The federal picture has narrowed. Compounders generally may prepare copies of FDA-approved drugs while those drugs sit on the FDA shortage list, or under narrower exceptions tied to an individual patient's need ^[1]. Over the past year, semaglutide, marketed as Ozempic and Wegovy, and tirzepatide, marketed as Mounjaro and Zepbound, came off those shortage lists, which shrank the federal basis for large-scale compounding of them ^[1]. State activity continued anyway, with states moving to fill what they see as gaps in oversight of compounding pharmacies, telehealth prescribers and peptide sellers ^[1].

The two main categories of compounders meet that state layer differently. So-called 503A pharmacies fill prescriptions for named patients and answer mainly to state boards of pharmacy, with less direct FDA oversight. 503B outsourcing facilities make larger batches without patient-specific prescriptions and register with FDA, which inspects them under stricter manufacturing standards ^[1]. Both still need a drug to be in shortage, or another statutory condition to be met, before they can compound a copy ^[1].

A separate account, published September 3, 2026 by attorney Martha Rumore, describes state medical, nursing and pharmacy boards taking an aggressive line on peptide prescribing ^[2]. Boards have issued warning notices, most though not all aimed at peptides labeled "research use only"; some warnings call peptides unapproved substances and say that giving them outside strict channels amounts to unprofessional conduct and malpractice ^[2]. Licenses have been suspended and practices have lost licenses, according to that article ^[2].

Eight states appear on its list of those that have issued warnings or are seen as more restrictive: Alabama, California, Connecticut, Louisiana, Mississippi, New Jersey, Ohio and South Carolina ^[2]. Mississippi's notice is a joint statement from its boards of nursing, pharmacy and medicine. South Carolina's says in part that a practitioner who buys, distributes or dispenses drugs or their components from an unpermitted facility "is aiding and abetting unlicensed practices in violating state law involving drugs and may be disciplined for unprofessional conduct" ^[2]. The same article says an FDA advisory panel recommended a month earlier that six peptides be added to the 503A Bulks List, which would allow them to be compounded eventually ^[2].

Why it matters for patients

Product availability and prescribing habits can differ by state even when the product and the process look the same to the patient ^[1]. Telehealth companies that treat patients across state lines carry the heaviest tracking burden, because requirements now vary jurisdiction by jurisdiction ^[1].

Sourcing is one area where the difference shows. Some boards warn that all prescription drugs, or the components used in compounded drugs, may be bought only from a business licensed by that state's board of pharmacy ^[2]. A few add that delegating care to nurse practitioners or physician assistants does not remove a physician's duty, and that waivers or disclaimers signed by patients do not transfer that responsibility either ^[2].

What happens next

Observers expect more state sessions to take up compounding and telehealth prescribing bills, more guidance or enforcement from state pharmacy boards, and possibly a response from FDA as it watches the compounded GLP-1 and peptide market following the lapse of the shortage designations ^[1]. Lawsuits testing how far states may go are considered plausible ^[1]. FDA and consumer protection agencies have already stepped up enforcement against deceptive marketing and seizures of imported peptides, the September article says ^[2].

No effective dates for individual state rules have been reported, and no federal legislation creating one national standard for these products has been reported either.